Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 25,528 |
|
|||||
| News | - | ||||||
| Day High | 0.7097 | Low High |
|||||
| Day Low | 0.6762 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galecto Inc | GLTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0195 | -2.78% | 0.6811 | 12:00:56 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.70 | 0.6762 | 0.7097 | 0.7006 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 39 | 25,528 | $ 0.7000899 | $ 17,872 | - | 0.50 - 3.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:05:57 | 1 | $ 0.69505 | USD |
Galecto Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.44M | 27.11M | - | 0 | -38.35M | -1.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galecto News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.66 | 0.72 | 0.651 | 0.69537 | 82,550 | 0.0211 | 3.20% |
| 1 Month | 0.7588 | 0.8424 | 0.60 | 0.7334835 | 167,507 | -0.0777 | -10.24% |
| 3 Months | 0.63 | 0.94 | 0.5612 | 0.746119 | 223,280 | 0.0511 | 8.11% |
| 6 Months | 0.57 | 0.94 | 0.50 | 0.6800146 | 289,998 | 0.1111 | 19.49% |
| 1 Year | 2.08 | 3.70 | 0.50 | 0.98557 | 366,905 | -1.40 | -67.25% |
| 3 Years | 6.07 | 16.41 | 0.50 | 3.11 | 277,376 | -5.39 | -88.78% |
| 5 Years | 15.77 | 17.99 | 0.50 | 3.28 | 243,909 | -15.09 | -95.68% |
Galecto Description
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
